CCA developed liposomal buprenorphine that lasts for over 8 wks in animals. This formulation (LE-Bup) may be used for chronic pain and addiction maintenance. Oral opioids may be misused or accidentally consumed by children. Long-acting opioids given in a medical setting have fewer chances for misuse or accidental ingestion. The Target Market is $1.3 B. LE-Bup is a better solution because medication is never placed in the hands of the patient.